Bloomberg Turnaround: How to Take Advantage of a $117 Billion Takeover Bid

The transcript discusses Pfizer's attempt to acquire AstraZeneca in 2014, which would have been the largest pharmaceutical takeover. Despite personal challenges, the speaker remained determined to keep the company independent, even with a low probability of success. Political and economic implications were significant, with lawmakers in various countries expressing concerns. AstraZeneca ultimately rejected the deal, focusing on its pipeline and future value for patients and shareholders. The situation galvanized the staff, leading to a renewed focus on delivering value.

What was the final offer made by Pfizer in their attempt to take over AstraZeneca?

• $150 billion

• $117 billion

• $200 billion

• $100 billion

How did the bankers assess the probability of the company remaining independent?

• Less than 10%

• About 50%

• Exactly 20%

• More than 75%

Which countries' lawmakers were critical of the takeover attempt?

• Britain, Sweden, and the US

• Canada, Australia, and Japan

• France, Germany, and Italy

• India, China, and Russia

What was one of the reasons AstraZeneca rejected Pfizer's offer?

• Lack of investor interest

• The offer did not reflect recent progress

• Political pressure from the US

• Insufficient legal support

How did AstraZeneca use the takeover attempt to benefit the company internally?

• By reducing staff

• By increasing marketing efforts

• By galvanizing the staff to deliver value

• By outsourcing research and development